Johnson & Johnson Seeking U.S. Approval For First New TB Drug In More Than 4 Decades

“Johnson & Johnson [J&J] said Monday that it is seeking U.S. approval for the first new type of medicine to fight deadly tuberculosis [TB] in more than four decades,” the Associated Press reports, adding, “The experimental drug, called bedaquiline, also would be the first medicine specifically for treating multi-drug resistant tuberculosis.” According to the news service, “J&J’s Janssen Research & Development unit created the drug, which was tested in several hundred patients with multi-drug resistant tuberculosis in two mid-stage studies lasting for six months,” and “[s]ome patients were studied for about 1 1/2 years.” The news service notes, “Janssen’s head of infectious diseases, Dr. Wim Pays, said the company will also apply for approval of bedaquiline in other countries where TB is very common” (Johnson, 7/2).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.